DR. JADE GARRETT ANDERSON M.D. NPI 1720098064

NPI Details

DR. Jade Garrett Anderson, M.D. is a medical oncology internal medicine in Amarillo, TX with 28 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Jade Garrett Anderson, M.D. NPI is 1720098064. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF MINNESOTA MEDICAL SCHOOL
Graduation Year:1998

The provider's business location address is:

1826 POINT WEST PKWY
AMARILLO, TX
ZIP 79124-167
Phone: (806) 358-8654
Fax: (806) 356-8687

The NPI 1720098064 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Protein measurement, serum (HCPCS:84165)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Unclassified drugs (HCPCS:J3490)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Folic acid level, serum (HCPCS:82746)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Blood creatinine level (HCPCS:82565)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Stool analysis for blood, by peroxidase activity (HCPCS:82272)
• Administration of influenza virus vaccine (HCPCS:G0008)

The enumeration date for this NPI number is 8/9/2006 and was last updated on 10/4/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.